Clinical Trial Update: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating daclatasvir with standard of care (pegylated interferon alfa-2a and ribavirin) in Japanese patients with Hepatitis C showed safety and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Daklinza (Daclatasvir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-09-11